Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SPRB |
---|---|---|
09:32 ET | 5431 | 3.1899 |
09:33 ET | 556 | 3.1889 |
09:39 ET | 400 | 3.16 |
09:42 ET | 300 | 3.165 |
09:50 ET | 238 | 3.18 |
09:51 ET | 306 | 3.19 |
09:55 ET | 1399 | 3.16 |
10:00 ET | 967 | 3.19 |
10:02 ET | 3813 | 3.2292 |
10:04 ET | 37800 | 3.33 |
10:06 ET | 826 | 3.3422 |
10:08 ET | 14015 | 3.17 |
10:09 ET | 11900 | 3.13 |
10:11 ET | 1850 | 3.14 |
10:18 ET | 200 | 3.1427 |
10:22 ET | 100 | 3.16 |
10:24 ET | 250 | 3.1621 |
10:26 ET | 200 | 3.1693 |
10:27 ET | 400 | 3.1528 |
10:33 ET | 1300 | 3.14 |
10:40 ET | 100 | 3.16 |
10:42 ET | 2200 | 3.19 |
10:51 ET | 100 | 3.1819 |
11:00 ET | 100 | 3.1588 |
11:02 ET | 500 | 3.2 |
11:09 ET | 5600 | 3.23 |
11:12 ET | 4110 | 3.2999 |
11:14 ET | 1262 | 3.2989 |
11:16 ET | 600 | 3.31 |
11:18 ET | 3427 | 3.29 |
11:27 ET | 150 | 3.2887 |
11:30 ET | 3200 | 3.23 |
11:36 ET | 100 | 3.245 |
11:39 ET | 100 | 3.245 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Spruce Biosciences Inc | 74.7M | -1.7x | --- |
Viracta Therapeutics Inc | 74.9M | -1.5x | --- |
Mustang Bio Inc | 75.5M | -0.9x | --- |
Anebulo Pharmaceuticals Inc | 75.6M | -9.0x | --- |
Mink Therapeutics Inc | 75.7M | -2.9x | --- |
Talaris Therapeutics Inc | 73.6M | -1.0x | --- |
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with poor disease control and anticipate topline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipate topline.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.88 |
Book Value | $4.74 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.